Physician profile
Fahd S Amjad
NPI 1477703312
$2,015,839.71
in general payments reported to CMS, 2019-2025
45 companies · $272K in 2025
The $272K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335K · 2020: $187K · 2021: $271K · 2022: $298K · 2023: $366K · 2024: $287K · 2025: $272K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $623K · Travel and Lodging: $153K · Consulting Fee: $92K · Honoraria: $30K · Food and Beverage: $25K · Education: $2,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $622,847.93 |
| Travel and Lodging | $153,385.53 |
| Consulting Fee | $92,127.83 |
| Honoraria | $29,565.00 |
| Food and Beverage | $24,533.24 |
| Education | $2,130.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,058,631.48 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Acadia Pharmaceuticals INC | $474,290.98 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $133,586.27 | 2019-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $87,840.58 | 2019-2025 | Duopa |
| Lundbeck LLC | $74,924.08 | 2019-2021 | |
| Kyowa Kirin, INC. | $64,079.79 | 2019-2024 | Nourianz |
| Amneal Pharmaceuticals LLC | $55,239.34 | 2019-2025 | Ongentys, Crexont, Ongentys 50mg Capsules 30 |
| Adamas Pharmaceuticals, INC. | $26,247.37 | 2019-2021 | |
| Mdd US Operations, LLC | $14,711.41 | 2019-2025 | Gocovri, Gocovri |
| Ucb, INC. | $9,425.18 | 2019-2024 | Rystiggo |
| Merz Pharmaceuticals, LLC | $6,132.44 | 2021-2025 | Xeomin, Inbrija, Ampyra |
| Sunovion Pharmaceuticals INC. | $3,997.05 | 2019-2022 | |
| Medtronic USA, INC. | $1,790.33 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $1,302.48 | 2019-2025 | |
| Lilly USA, LLC | $446.88 | 2019-2025 | Amyvid, Kisunla |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $410.83 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $380.99 | 2022-2025 | Qelbree |
| Celgene Corporation | $277.43 | 2021-2025 | Zeposia |
| Abbott Laboratories | $234.94 | 2019-2025 | Infinity |
| Biogen, INC. | $210.31 | 2019-2024 | Tysabri, Vumerity, Plegridy |
| Revance Therapeutics, INC. | $194.05 | 2024 | Daxxify, Daxi |
| Genzyme Corporation | $175.87 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $174.17 | 2023-2024 | Purified Cortrophin Gel |
| Tg Therapeutics, INC. | $172.89 | 2024 | |
| Alexion Pharmaceuticals, INC. | $158.88 | 2019-2024 | Ultomiris |
| Amgen INC. | $97.91 | 2019-2025 | Uplizna |
| Avion Pharmaceuticals | $97.52 | 2022-2023 | Dhivy |
| Acorda Therapeutics, INC | $92.86 | 2019-2023 | Inbrija, Ampyra |
| Medtronic, INC. | $64.99 | 2023 | Percept Pc Brainsense |
| Ipsen Biopharmaceuticals, INC | $52.53 | 2020-2025 | Dysport |
| Boston Scientific Corporation | $47.59 | 2024 | Vercise |
| Genentech USA, INC. | $45.54 | 2019-2025 | Ocrevus Zunovo |
| Avanir Pharmaceuticals, INC. | $44.51 | 2021-2022 | |
| Allergan, INC. | $40.89 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $29.14 | 2021 | |
| Nevro Corp. | $28.01 | 2022 | |
| Emd Serono, INC. | $26.44 | 2019-2023 | Mavenclad |
| Mallinckrodt Hospital Products INC. | $26.44 | 2025 | Acthar |
| Axsome Therapeutics, INC. | $25.51 | 2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $19.33 | 2021 | |
| Eisai INC. | $17.89 | 2024 | |
| Vertical Pharmaceuticals, LLC | $16.36 | 2019 | |
| Horizon Therapeutics Plc | $15.92 | 2023 | Uplizna |
| Saol Therapeutics INC. | $14.31 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fahd Amjad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.